Nanomedicine applies the tools and knowledge of nanoscience to improve human health. By designing and engineering materials at the nanoscale, researchers can create solutions for diagnosing, treating, and preventing disease with greater precision and efficiency than ever before.

At the Group of Nanoparticles and Nanocomposites, our work in nanomedicine focuses on understanding and controlling how nanomaterials interact with biological systems. This includes tailoring their size, shape, and surface chemistry to ensure they are effective, targeted, and safe.

One key area of interest is the development of nanoparticles that can deliver drugs directly to specific cells or tissues, reducing side effects and improving therapeutic outcomes. Another is the design of nanomaterials that act as imaging agents, enabling doctors and scientists to visualise diseases at early stages. We also explore multifunctional nanostructures that combine diagnostic and therapeutic capabilities, paving the way for personalised medicine.

Our research often involves creating hybrid materials that combine inorganic and organic components, offering unique combinations of properties. These materials can respond to specific biological signals or environmental changes, providing new strategies for controlled drug release or targeted action.

Advances in nanomedicine depend on a multidisciplinary approach, combining expertise in chemistry, physics, biology, and materials science. In our group, collaborations with clinicians, biologists, and other scientists are essential to ensure that our materials are not only innovative in the lab but also relevant and safe for real-world applications.

By applying the principles of nanoscience to healthcare challenges, nanomedicine has the potential to transform diagnostics, therapies, and patient care — and our group contributes to making that transformation a reality.